Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression: the Prospective VASCUL-AID Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-30

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction:

Peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA) are vascular conditions associated with significant morbidity and mortality, with 25% of AAA patients and 23% of PAD patients being at a high risk of developing cardiovascular disease. Cardiovascular risk management can reduce the risk of major adverse cardiovascular events in AAA patients from 43% to 14%. However, cardiovascular risk is not always adequately addressed in these patients. The VASCUL-AID-PRO study aims to deliver clinically relevant prediction models using artificial intelligence and machine learning of patient outcomes to enable personalized management of vascular disease.

Method:

VASCUL-AID-PRO is a multi-centre international prospective cross-sectional study aiming to include 500 AAA patients and 600 PAD patients across 6 European centres. The aim is to achieve a follow-up time up to 4 years.

The study will include individuals aged 40-90 with either an abdominal aortic aneurysm (infrarenal, juxtarenal, pararenal, or suprarenal abdominal aortic aneurysm) or Fontaine stage 2 peripheral arterial disease.

The VASCUL-AID-PRO study will gather a variety of data from all participants, including clinical data, blood and tissue samples, cardiovascular lab values, imaging data, electrocardiograms, data from wearables and quality of life.

This data gathered will be used to further develop the multi model prediction models being developed on 5000 AAA and 6000 PAD patients included in the currently ongoing VASCUL-AID-RETRO study, with the aim of providing a clinically relevant prediction models of disease progression and other cardiovascular disease for AAA and PAD patients.

Furthermore, the models developed in the VASCUL-AID studies will be internally validated using a subset of patients from the VASCUL-AID-PRO study.

Ethical considerations:

Ethical and legal considerations are paramount throughout the VASCUL-AID project. To address these concerns, an ELSI framework will be developed and integrated into all stages of the project. This framework will be continuously updated to ensure alignment with evolving ethical, legal, and social standards. This framework will specifically focus on patient safety, data handling, AI regulation and implementation, and potential biases associated with AI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

NCT06206369

Aneurysm Abdominal Peripheral Arterial Disease

RECRUITING

AI-enhanced Imaging Analysis to Predict Post-EVAR

NCT06592105

Aortic Aneurysm

NOT_YET_RECRUITING

REGISTRY on the Implementation of Artificial Intelligence in the Automatic Analysis of Vascular Network Segmentation

NCT06451315

Abdominal Aortic Aneurysm

RECRUITING

Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence

NCT06250998

AAA - Abdominal Aortic Aneurysm

RECRUITING

Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment

NCT04773223

Juxtarenal Aortic Aneurysm Pararenal Aneurysm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aorta Aneurism Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AAA

* Males/females between 40 and 90 years of age.
* Males and females with AAA at inclusion, any diameter \>3 cm (or 1.5x larger than their non-dilated part of the aorta).
* Include: infrarenal, juxtarenal, pararenal, suprarenal abdominal aortic aneurysms.

Without prior AAA surgery or or planned AAA surgery within 6 months after inclusion.

No interventions assigned to this group

PAD

* Males/females between 40 and 90 years of age.
* Patients with peripheral arterial disease stage Fontaine 2a and 2b at inclusion. Medical history (e.g. CLTI) does not matter, current disease stage is leading at inclusion.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males/females between 40 and 90 years of age.
* Males and females with AAA at inclusion, any diameter \>3 cm (or 1.5x larger than their non-dilated part of the aorta).
* Include: infrarenal, juxtarenal, pararenal, suprarenal abdominal aortic aneurysms.

* Males/females between 40 and 90 years of age.
* Patients with peripheral arterial disease stage Fontaine 2a and 2b at inclusion. Medical history (e.g. CLTI) does not matter, current disease stage is leading at inclusion.

Exclusion Criteria

Patients with:

* Insufficient schooling or sensorial deficits that interfere understanding informed consent.
* Not able to use the VASCUL-AID mobile health app (that will be provided in Dutch, English, German, Portuguese, Serbian, Finish, Swedish languages).
* Proven or highly suspected for infected, mycotic AAA
* Previous AAA surgery or planned for an AAA surgery within 6 months
* Ruptured AAA

Patients with:

* Insufficient schooling or sensorial deficits that interfere understanding informed consent.
* Not able to use the VASCUL-AID mobile health app (provided in Dutch, English, German, Portuguese, Serbian, Finnish, Swedish languages).

Minimum Eligible Age

40 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No